Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024.
2024年11月4日都柏林(GLOBE NEWSWIRE) -- avadel pharmaceuticals公司(Nasdaq: AVDL)是一家专注于改变药物以改变生活的生物制药公司，宣布今天将于2024年11月12日周二上午8:30 Et召开电话会议和直播网络视频会议，进行公司更新并讨论截至2024年9月30日第三季度的财务业绩。
To access the conference call, investors are invited to dial (800) 579-2543 (U.S. and International) and reference the conference ID AVADEL. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, . A replay of the webcast will be archived on Avadel's website for 90 days following the event.
要参加电话会议，投资者可拨打(800) 579-2543(美国和国际)，并参考会议ID AVADEL。可通过访问该公司网站的投资者关系部分来获取电话会议的现场音频网络视频。网络视频会的重播将在活动结束后的90天内存档在avadel的网站上。
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel's commercial product, LUMRYZ, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years and older with narcolepsy. For more information, please visit .
关于Avadel Pharmaceuticals，plc
avadel pharmaceuticals公司(Nasdaq: AVDL)是一家专注于改变药物以改变生活的生物制药公司。我们的方法包括将创新解决方案应用于开发能够解决患者在当前治疗选择中面临的挑战的药物。avadel的商业产品LUMRYZ获得美国食品药品监督管理局(FDA)批准，作为首个也是唯一一款控制癫痫或白天过度嗜睡(EDS)的奥斯巴特，适用于7岁及以上患有嗜睡病的患者。欲了解更多信息，请访问。
Investor Contact:
Courtney Mogerley
Precision AQ
Courtney.Mogerley@precisionAQ.com
(212) 698-8687
投资者联系人：
Courtney Mogerley
Josh.Rappaport@precisionaq.com
Courtney.Mogerley@precisionAQ.com
(212) 698-8687
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
媒体联系人：
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
译文内容由第三方软件翻译。
